Comparison of Tamoxifen and Toremifene as Adjuvant Treatment in Node-negative Postmenopausal Breast Cancer
Journal of the Korean Surgical Society
;
: 283-286, 2002.
Article
in Korean
| WPRIM
| ID: wpr-187917
ABSTRACT
PURPOSE:
To evaluate the differences in therapeutic efficacy and toxicity profiles between adjuvant toremifene and tamoxifene in postmenopausal breast cancer patients.METHODS:
Toremifene 40 mg (n=115) and tamoxifen 20 mg (n =116) were administered daily for more than 2 years after curative surgery for lymph node-negative breast cancer. Toxicity profiles were compared between the two groups and the patient survival rate was also analyzed.RESULTS:
Sweating and hot flashes were the most common symptoms in the two groups (toremifene vs. tamoxifen= 47.8% vs. 49.1%). Increase of vaginal discharge (39.1% vs. 36.2%) and weight gain (21.7% vs. 24.1%) were the next following adverse effects. There was no significant difference in adverse effect between the two groups. During the median follow-up period of 25 months (range 9~38 months), five (4.3%) and four (3.3%) patients treated by toremifene and tamoxifen, respectively, had recurrent disease.CONCLUSION:
The clinical outcome and adverse effect profiles of toremifene were similar to those of tamoxifen. Toremifene at 40 mg/day seems to be as safe and effective as tamoxifen at 20 mg/day in the treatment of postmenopausal, node-negative, breast cancer. However, a longer follow-up study is needed to verify this.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Sweat
/
Sweating
/
Tamoxifen
/
Breast
/
Breast Neoplasms
/
Weight Gain
/
Survival Rate
/
Follow-Up Studies
/
Toremifene
/
Vaginal Discharge
Type of study:
Observational study
/
Prognostic study
Limits:
Humans
Language:
Korean
Journal:
Journal of the Korean Surgical Society
Year:
2002
Type:
Article
Similar
MEDLINE
...
LILACS
LIS